TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Onesource Specialty Pharma Ltd.

ONESOURCE on NSE · 19 Nov 2026

NIFTY 500

1,602.90 ▲ +1.05 % on the day

Overview Technical Risk & rank Results Accounts Filings Guidance & governance

Guidance tracker

What ONESOURCE guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
03 Nov 2026Earnings call transcript for Q2 FY27 (quarter ended September 30, 2026) of OneSource Specialty Pharma Limited, held October 27, 2026, filed under Regulation 30. Management (CEO Neeraj Sharma) said revenue rose 37% year-on-year and 15% sequentially to more than INR5 billion, EBITDA grew 53% year-on-year and 32%... NSE copy No results filed since
31 Jul 2026OneSource Specialty Pharma filed the transcript of its Q1 FY27 earnings call held July 25, 2026, for the quarter ended June 30, 2026. Management said revenue was INR4,490 million, up 37% year-on-year, and EBITDA was INR1,233 million, up 39% year-on-year and 34% sequentially. Management reiterated its FY28 outlook... NSE copy No results filed since
19 May 2026Transcript of the Q4 and FY26 earnings conference call held May 13, 2026, filed under Regulation 30 for OneSource Specialty Pharma Limited. Management said Q4 FY26 revenue was INR4,282 million, up 47% sequentially, with Q4 EBITDA of INR919 million; FY26 revenue was INR14,216 million, down 2% year-on-year, and FY26... NSE copy -+37.2 %+2.1 %
13 May 2026OneSource Specialty Pharma filed its Q4FY26 and FY26 press release and investor presentation on May 13, 2026. Q4FY26 revenue was ₹4,282 million, up 47% QoQ; EBITDA was ₹919 million (21% margin) versus ₹173 million in Q3FY26; adjusted PAT was ₹390 million, with adjusted EPS of ₹3.4. FY26 revenue was ₹14,216 million... NSE copy -+37.2 %+2.1 %
30 Jan 2026OneSource Specialty Pharma filed the transcript of its Q3 FY26 earnings call (held January 24, 2026) for the quarter ended December 31, 2025. Management said Q3 revenue was about INR2,903 million, down 26% year-on-year, with EBITDA of INR173 million and adjusted PAT loss of INR472 million (adjusted diluted EPS... NSE copy --+1.7 %
23 Jan 2026OneSource Specialty Pharma filed its Q3FY26 press release and investor presentation (quarter ended December 31, 2025), with the consolidated results. Q3FY26 revenue was ₹2,903 million, down 26% YoY; EBITDA was ₹173 million (6% margin), down 88% YoY; Adjusted PAT was (₹472) million with Adjusted EPS of (₹4.1).... NSE copy --+1.7 %
18 Nov 2025OneSource Specialty Pharma filed the transcript of its Q2 FY26 earnings conference call held on November 12, 2025, for the quarter and half year ended September 30, 2025. Management (Neeraj Sharma, CEO and MD) said Q2 revenue was INR3,758 million, up 12% year-on-year, with EBITDA of INR1,065 million (up 37%) at a... NSE copy --26.0 %-19.6 %
12 Nov 2025OneSource Specialty Pharma filed its Q2FY26 earnings investor presentation dated November 12, 2025, after a board meeting held November 11, 2025 (16:10 to 16:35 hrs IST). Q2FY26 revenue was ₹3,758m ($43.1m), up 12% YoY; EBITDA was ₹1,065m ($12.2m), up 37% YoY, with a 28% margin (about 506 bps YoY improvement).... NSE copy --26.0 %-19.6 %
26 Sep 2025OneSource Specialty Pharma filed an investor presentation on the Board-approved strategic transaction to acquire the European CDMO business of Steriscience and the anti-infective business of Brooks Steriscience, via a scheme of merger. The transaction values OneSource at $2.7 billion, an 18.6% premium to the... NSE copy -+452.8 %+0.3 %
12 Aug 2025Transcript of OneSource Specialty Pharma's Q1 FY26 earnings call (held August 5, 2025), filed under Regulation 30 for the quarter ended June 30, 2025. Management said Q1 revenue was INR 3,273 million, up 12% year-over-year, with EBITDA up 37% to INR 885 million and margin up about 500 bps to 27%. Adjusted PAT was... NSE copy -+452.8 %+0.3 %
12 May 2025Transcript of OneSource Specialty Pharma's Q4 and full-year FY25 earnings call held May 06, 2025, with management Arun Kumar (Founder and Non-Executive Chairperson), Neeraj Sharma (CEO and MD) and Anurag Bhagania (CFO). Management reported Q4 revenue of INR4,260 million (up 22%), Q4 operating EBITDA of INR1,825... NSE copy -+317.5 %-1.2 %
04 Feb 2025OneSource Specialty Pharma filed the transcript of its Q3 and 9-month FY25 earnings conference call held on January 29, 2025. Management reported Q3 revenue of INR393 crores and EBITDA of INR143 crores, with a 36% EBITDA margin; 9-month revenue was about INR1,000 crores and 9-month EBITDA about INR284 crores.... NSE copy ---2.2 %

Filings tagged as guidance, newest first (12 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
18 Aug 2026Credit ratingOneSource Specialty Pharma Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on August 18, 2026 regarding a credit rating action by India Ratings & Research. India Ratings upgraded the long-term rating on INR 11,250.51 million of bank loan facilities to IND A/Positive from IND A-, and... NSE copy
13 May 2026Management changeOneSource Specialty Pharma's board, meeting held May 13, 2026 (11:30 to 12:55 hrs IST), approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with the auditors' report enclosed. The auditors' report on the annual results carries an unmodified opinion, per the... NSE copy
05 Mar 2026Credit ratingOneSource Specialty Pharma Limited filed intimation under Regulation 30 of SEBI Listing Regulations on March 5, 2026 regarding credit ratings. CareEdge Ratings (CARE) reaffirmed bank facilities at CARE BBB+; Stable (long-term) and CARE A3+ (short-term), and the ratings were withdrawn at the company's request. CARE... NSE copy
30 Jan 2026Credit ratingOneSource Specialty Pharma filed the transcript of its Q3 FY26 earnings call (held January 24, 2026) for the quarter ended December 31, 2025. Management said Q3 revenue was about INR2,903 million, down 26% year-on-year, with EBITDA of INR173 million and adjusted PAT loss of INR472 million (adjusted diluted EPS... NSE copy
18 Nov 2025Legal or regulatoryOneSource Specialty Pharma filed the transcript of its Q2 FY26 earnings conference call held on November 12, 2025, for the quarter and half year ended September 30, 2025. Management (Neeraj Sharma, CEO and MD) said Q2 revenue was INR3,758 million, up 12% year-on-year, with EBITDA of INR1,065 million (up 37%) at a... NSE copy
26 Sep 2025Legal or regulatoryOneSource Specialty Pharma's board approved a composite scheme of arrangement and amalgamation (merger by absorption) with Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte Limited (Singapore) and Strides Pharma Services Private Limited, with OneSource as the ultimate... NSE copy
12 Aug 2025Credit ratingTranscript of OneSource Specialty Pharma's Q1 FY26 earnings call (held August 5, 2025), filed under Regulation 30 for the quarter ended June 30, 2025. Management said Q1 revenue was INR 3,273 million, up 12% year-over-year, with EBITDA up 37% to INR 885 million and margin up about 500 bps to 27%. Adjusted PAT was... NSE copy
08 Jul 2025Legal or regulatory, AuditorOneSource Specialty Pharma Limited (formerly Stelis Biopharma) filed an intimation dated May 5, 2025 that its board, at a meeting on that day, approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with the auditors' report enclosed. The board also approved... NSE copy
21 Jun 2025AuditorThe Exchange has sought clarification from Onesource Specialty Pharma Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review...
04 Jun 2025Credit ratingOneSource Specialty Pharma Limited filed an intimation under Regulation 30 and Regulation 51 of the SEBI Listing Regulations, dated June 04, 2025, informing exchanges of a credit rating. India Ratings & Research assigned 'IND A-' with Positive Outlook to the company's bank facilities, with the press release dated... NSE copy
05 May 2025Legal or regulatory, Management changeBoard outcome filed on May 5, 2025 following a meeting held that day (15:45 to 19:15 IST) by OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited). The board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with the auditors' report... NSE copy
21 Feb 2025Credit ratingOneSource Specialty Pharma filed a Regulation 30/51 intimation to BSE and NSE enclosing a CARE Ratings press release dated February 20, 2025. CARE upgraded long-term bank facilities to CARE BBB+; Stable from CARE BB+, with the amount enhanced from ₹120.10 crore to ₹215 crore, and removed them from Rating Watch with... NSE copy
30 Jan 2025Legal or regulatoryOneSource Specialty Pharma Limited (formerly Stelis Biopharma) filed its unaudited standalone financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 29, 2025, with an unmodified limited review conclusion from Deloitte Haskins & Sells. Q3 FY25 revenue from... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (13 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in